This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

July 7th, 2025

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

MODALIS Therapeutics and The Broad Institute Enter into License Agreement to Advance Therapies for LAMA2-Related Muscular Dystrophy

Tokyo, Japan – July 7th, 2025 – MODALIS Therapeutics Corporation ("MODALIS") announced that it has entered into a license agreement with The Broad Institute, Inc. ("Broad"), under which MODALIS obtains rights to intellectual property related to gene therapy for LAMA2-related muscular dystrophy (also known as MDC1A).

Under the terms of the agreement, MODALIS receives a non-exclusive, worldwide license to certain patent rights held by Broad and its affiliated institutions. The licensed rights will support MODALIS's development and commercialization of AAV-based gene therapy, MDL-101, targeting LAMA2 deficiency.

"We are honored to work with Broad, a globally recognized science engine in biomedical innovation," said Haru Morita, Chief Executive Officer of MODALIS. "Broad's MYOAAV has excellent muscle targeting properties and can efficiently and selectively deliver genes to skeletal and cardiac muscles. This allows our GNDM payload to be delivered to muscles at lower doses without causing problems in non-target organs such as liver. This agreement strengthens our intellectual property position and enables us to accelerate the development of potentially transformative treatments for patients affected by MDC1A."

While financial terms of the agreement were not disclosed, the agreement includes milestone payments to Broad based on clinical and regulatory progress, as well as royalties on future product sales.

About MDL-101

MDL-101 is an experimental, epigenetic editing therapy that is being developed for the treatment of LAMA2-Congenital Muscular Dystrophy (LAMA2-CMD). MDL-101 is comprised of a guide nucleotide targeting LAMA1 gene, a highly homologous sister gene of the disease-causing gene LAMA2, enzyme-null Cas9 (dCas9) fused with trans-activating domain driven by a muscle-specific promoter and coded in a muscle-specific AAV vector. MDL-101 upregulates LAMA1 gene products in patients' muscle tissue to compensate for loss-of-function caused by mutation of LAMA2, and therefore has the potential to provide a one-time, durable treatment to benefit people living with LAMA2-CMD.

About Modalis

Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit https://www.modalistx.com/en/.